Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MASSIV: MDA with Ivermectin and Dihydroartemisinin-piperaquine for Malaria
NCT03576313Phase 3Completed
- Sponsor
- London School of Hygiene & Tropical Medicine
- Start
- Aug 2018
- Primary completion
- Dec 2019
- Modality
- Bivalent/Multivalent Binders, Nucleic Acid-Directed Small Molecules, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of CHILD-IVITAB, dihydroartemisinin + piperaquine in malaria, sponsored by London School of Hygiene & Tropical Medicine. Started Aug 2018; status: completed.
02
Drugs
CHILD-IVITABdihydroartemisinin + piperaquine
03
Conditions
malaria
Beyond the preview
Go deeper on NCT03576313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03576313.